secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2022-05-25T23:59:59+00:00
Accession:  0001437749-22-013555
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SVP of Clinical Operations Harry Alcorn resigns from DiaMedica; separation agreement includes salary continuation
--------------------------------------------------------------------------------

- Harry Alcorn, Jr., Pharm.D., SVP of Clinical Operations, resigned effective May 23, 2022.
- Separation agreement provides salary continuation for 9 months (up to 12 if unemployed), COBRA, pro-rata bonus, and option acceleration.
- Entered consulting agreement at $200/hour; no fees while receiving salary continuation.
- Alcorn must cooperate with transition, maintain confidentiality, and non-disparagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922013555/0001437749-22-013555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922013555/dmtp20220524_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-013555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer